Health Economics/Outcomes Research

(238) A Web-Based Survey of Patients Dispensed Viagra Connect Behind the Counter in the UK: An Evaluation of The Effectiveness of Additional Risk Minimization Measures

(221) Adjuvant Radiation Therapy and Mortality in Older Women with Early-Stage Endometrial Cancer: An Analysis Using The SEER-Medicare Linkage

(J) Economic Evaluation of Sacubitril/Valsartan for The Treatment of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) in Indonesia

(I) Impact of Clinical Pharmacist Interventions on Patients' Quality of Life (QoL) and Influencing Risk Factors Associated with Poor QoL in Systemic Lupus Erythematosus Disorder Patients

(K) Risk of Mortality with Early-Stage Nonadherence to The Regimen in Patients with Drug-Susceptible Tuberculosis: A Nationwide Linkage Database

(201) Assessment of Barriers for Medication Non-Adherence in Ambulatory Psychiatric Patients at Tertiary Care Hospital

(185) Assessment of Financial Toxicity and Its Association with Quality of Life Among Radiation Oncology Patients: A Cross-Sectional Study in India

(195) Association Between Health Status and Access to Treatment in a Sample of Women Recovering from Substance Use Disorders

(218) Association of Joint Replacement Registries with Burden of Revision Changes

(222) Cardiovascular and Renal Complications Among Patients with Chronic Kidney Disease (CKD) in the Netherlands

(234) Challenges of Using Real-World Evidence for Regulatory Decisions: 4 Key Issues

(187) Clinical and Economical Impact of Parenteral Nutrition Among the Neonates Admitted to Neonatal Intensive Care Unit (NICU): A Prospective Interventional Study

(206) Comparative Effect of Oral Anticoagulants on Home Time Loss and Cost: The Role of Frailty

(231) Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

(229) Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Cancer

(230) Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

(228) Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employees with Breast, Skin, GI, Female, Male, and "Other" Cancers

(209) Consumers Perceptions, Expectations & Satisfaction About Patient Care Services Provided by The Community Pharmacist

(200) Cost of Illness and Economic Burden of COVID-19 in Private Tertiary Care Hospital

(236) Cost of Long COVID-19 Following Severe Disease – A Healthcare Database Analysis

(220) Cost-Effectiveness of IV Antibiotics Therapy for Children with Acute Gastroenteritis in a Secondary Care Hospital in South India

(202) Determinants of Treatment Outcomes in HIV Patients with Opportunistic Infections: A Prospective Study in Southern India

(215) Determining Patient Preferences for The Medical Management of Osteoporosis Using Conjoint Analysis

(198) Diagnostic Suspicion Bias in Studies of Thiazide and Non-Melanoma Skin Cancer – A Cohort Study

(181) Do More Rigorously Tested Drugs Garner Higher Prices Upon Market Launch?

(B) Description of Concurrent CKD and HF by Race and Ethnicity Distribution in the US

(237) Duration of COVID-19 and Long COVID – A US Healthcare Database Analysis

(240) Estimated Costs of Severe Adverse Drug Reactions Resulting in Hospitalization in The Veterans Health Administration

(197) Evaluation of a Community Pharmacy-Based Diabetes Care: Patients Self-Reported Outcomes Using Validated Questionnaires and Clinical Outcomes

(217) Factors Affecting Physicians' Prescribing Practices Through Pharmaceutical Marketing Mix Strategies: A Cross-Sectional Study in Jordan

(190) Health Related Quality of Life in HIV Patients: A Decennial Data Systematic Review and Meta-Analysis

(216) Healthcare Cost Consciousness Among Physicians and Their Attitudes Towards Controlling Costs in Jordan: A Cross Sectional Study

(225) Healthcare Cost of Retreatment Following Ureteroscopy or Percutaneous Nephrolithotomy for Urinary System Stone Disease

(235) Healthcare Costs of COVID-19 Versus Flu and Pneumonia – A Payer Perspective

(203) Healthcare Resource Utilisation Associated with Intermittent Oral Corticosteroid Use in Asthma

(182) Health-Related Quality of Life of Indonesian Cancer Patients: Comparison of EORTC QLQ C30 and EQ5D Questionnaires

(208) Impact of Immunosuppressant Therapies and Transplantation on Health- Related Quality of Life Among Renal Transplant Recipients at a National Referral Hospital in Kenya

(180) Impact of the COVID-19 Pandemic on Assessing Incidence and Healthcare Resource Use of Myasthenia Gravis, Parkinson's Disease, and Hidradenitis Suppurativa Patients in the United States

(205) Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from The Ontario Best Practices Research Initiative (OBRI)

(189) Incidence of Adverse Events of Special Interest in The Pre-Covid and Active Covid ERA as Historical Comparators for Post-Marketing Safety Surveillance of SARS-CoV-2 Vaccines

(223) Incidence of RSV Lower Respiratory Tract Infections Among Infants Considering Effects of Palivizumab Immunoprophylaxis

(214) Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission

(207) Medical Conditions Associated with Hospitalization Among Outpatients with COVID-19: Findings from Real-World Data

(224) Operating Characteristics of COVID-19 Diagnosis Code in Hospital Settings

(188) Patient-Reported Challenges for Self-Management of Asthma; Findings of a Focused Group Study

(232) Real-World Cost-Effectiveness of Adrenocorticotropic Hormone Versus Oral Prednisolone for Children with West Syndrome

(226) Risk of Second Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients with Extended Anticoagulant Treatment: A Retrospective Cohort Study

(183) Safety and Efficacy of Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone in Moderate-To-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

(219) Screening For, Diagnosing and Surgically Treating Breast Cancer in the Unites States: Impact of the COVID-19 Crisis

(227) Self-Reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders

(191) Statistical Evaluation of Surrogate Endpoints to Optimise Trial Design and Speed Up Decision Making Through the Use of Early Outcomes: A Case Study Using Observational Patient-Level Data

(194) Systematic Literature Review on Health-Related Quality of Life Associated with Chronic Cough

(192) Systematic Literature Review on The Cost-Effectiveness of Current Treatments for Chronic Cough

(193) Systematic Literature Review on The Economic Burden of Chronic Cough

(210) The Association of Opioid Use with Risk of ICU Admission and Mortality in The Adult Dutch Population

(186) The Best of All Worlds: Development of a Consolidated Data Model to Expand the Ability to Generate Real-World Evidence

(199) The Care Cascade of Hepatitis C Virus in The Direct-Acting Antiviral Era: A Systematic Review and Meta-Analysis

(196) The Effect of Generic Market Entry on HIV Treatment Cost in Portugal

(241) The Health Economics of Metastatic Hormone Sensitive and Non-Metatastatic Castration-Resistant Prostate Cancer – A Systematic Literature Review

(184) The Quality of Reporting Methods and Results of Cost-Effectiveness Analyses in India: A Methodological Systematic Review

(233) Ticagrelor for Acute Coronary Disease to Prevent Cardiovascular Events: Cost-Effectiveness Analysis in Indonesia

(204) Treatment Outcomes for Advanced and Recurrent Endometrial Cancer Following Platinum-Based Chemotherapy in Canada

(213) Understanding The Impact of the COVID-19 Pandemic on Disease Burden Among Medicaid Patients in the United States: An Analysis of Alterations in Healthcare Resource Utilization

(212) Understanding The Impact of the COVID-19 Pandemic on Disease Burden Among Patients with Employer Sponsored Insurance in the United States: An Analysis of Alterations in Healthcare Resource Utilization